DDInter743 DDInter1676
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A7
Fluconazole {u} (Compound) upregulates {v} (Gene) MELK
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Fluconazole {u} (Compound) downregulates {v} (Gene) WFS1
Fluconazole {u} (Compound) causes {v} (Side Effect) Rigors
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Fluconazole {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Fluconazole (Compound) binds CYP3A7 (Gene)
Fluconazole (Compound) upregulates MELK (Gene)
Fluconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Fluconazole (Compound) downregulates WFS1 (Gene)
Fluconazole (Compound) causes Rigors (Side Effect)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole